Journal of Peking University(Health Sciences) ›› 2018, Vol. 50 ›› Issue (6): 1117-1119. doi: 10.19723/j.issn.1671-167X.2018.06.032

• Article • Previous Articles     Next Articles

A case of gout secondary to primary myelofibrosis

Lan-lan JI,Yan-jie HAO,Zhuo-li ZHANG()   

  1. Department of Rheumatology and Immunology,Peking University First Hospital, Beijing 100034, China
  • Received:2018-07-09 Online:2018-12-18 Published:2018-12-18
  • Contact: Zhuo-li ZHANG E-mail:zhuoli.zhang@126.com

Abstract:

A 52-year-old man was referred to our department with a 2-year history of polyarthritis. He was diagnosed as gout due to acute arthritis of bilateral feet dorsum 2 years ago,but he didn’t receive any standard treatment. 1 year ago,there were more and more joints evolved during the gout attack,and many subcutaneous nodules occurred. When he presented to our clinic 1 month ago,the urate acid level was as high as 715 μmol/L. Moreover,we could find bone erosion in the X rays of his hand and foot,as well as synovitis,double contour sign and tophus on the ultrasound examination. The diagnosis of gout was clearly and definitely. However,he had leukocytosis and thrombocytosis for 4 years in the past history,and the urate acid level was only 400 μmol/L at that time. He also had well-controlled hypertension. The family history was unremarkable. Furthermore,we found megalosplenia on his physical examination. The bone marrow examination showed myelofibrosis and JAK2 V617F gene was positive. He was diagnosed as primary myelofibrosis and treated with interferon-α,together with urate acid-lowing therapy (febuxostat 60 mg once daily). Following-up for 1 year,the dosage of febuxostat decreased to 40 mg once daily,and the patient didn’t have gout attack again,some of the tophus diminished,and the urate acid level ranged from 400 to 500 μmol/L. Gout is a common disease in clinical practice,usually combined with metabolic syndrome,chronic renal failure and specific drugs using (diuretic and calcineurin inhibitors). However,it is relatively rare to see gout associated with myeloproliferative diseases,including polycythemia vera,primary thrombocythemia,primary myelofibrosis and chronic myelocytic leukemia.In these diseases,the turnover of nucleic acids is greatly augmented,and an excess of purine metabolites,including uric acid,is released. In the natural course of gout,the appearance of tophus from the first onset of arthritis usually takes several years. This patient only had one traditional risk factor,but his urate acid level was remarkably high and he developed tophus in a short term. After treatment of primary myelofibrosis,the symptom of gout partially alleviated. Careful physical examination and medical history taking lead to the diagnosis of secondary gout,which should be reminded in the daily practice.

Key words: Secondary gout, Tophus, Primary myelofibrosis, Myeloproliferative diseases

CLC Number: 

  • R593

Figure 1

The X-ray of bilateral wrists,hands (A) and feet (B),the arrows show the bone erosion"

Figure 2

The double contour sign of left talus. We can see the double contour sign of talus in the transverse scan (arrow)"

Figure 3

Tophus of right foot,there was a mass with low-high mixed echo above the talonavicular joint,with clear bound line and spotted Doppler signal (arrow)"

[1] 中华医学会风湿病学分会. 2016中国痛风诊疗指南[J]. 中华内科杂志, 2016,55(11):892-899.
[2] Neogi T, Jansen TLTA, Dalbeth N , et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Ann Rheum Dis, 2015,74(10):1789-1798.
doi: 10.1136/annrheumdis-2015-208237 pmid: 4602275
[3] Yü TF . Secondary gout associated with myeloproliferative diseases[J]. Arthritis Rheum, 1965,8(5):765-771.
doi: 10.1002/art.1780080439 pmid: 5216775
[4] Gutman AB . The past four decades of progress in the knowledge of gout, with an assessment of the present status[J]. Arthritis Rheum, 1973,16(4):431-445.
doi: 10.1002/(ISSN)1529-0131
[5] Takahashi H, Hattori A, Shibata A . Profile of blood coagulation and fibrinolysis in chronic myeloproliferative disorders[J]. Tohoku J Exp Med, 1982,138(1):71-80.
doi: 10.1620/tjem.138.71 pmid: 6959382
[6] Barbui T, Carobbio A, Cervantes F , et al. Thrombosis in primary myelofibrosis: incidence and risk factors[J]. Blood, 2010,115(4):778-782.
doi: 10.1182/blood-2009-08-238956 pmid: 19965680
[7] Liu TT, Chen JB, Chen WJ , et al. Idiopathic myelofibrosis associated with renal extramedullary hematopoiesis and nephrotic syndrome: case report[J]. Chang Gung Med J, 2000,23(3):169-174.
pmid: 15641221
[1] Pu-li ZHANG,Hong-xia YANG,Li-ning ZHANG,Yong-peng GE,Qing-lin PENG,Guo-chun WANG,Xin LU. Value of serum YKL-40 in the diagnosis of anti-MDA5-positive patients with dermatomyositis complicated with severe pulmonary injury [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1055-1060.
[2] Lan LUO,Xiao-yan XING,Yun-shu XIAO,Ke-yan CHEN,Feng-yun-zhi ZHU,Xue-wu ZHANG,Yu-hui LI. Clinical and immunological characteristics of patients with anti-synthetase syndrome complicated with cardiac involvement [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1078-1082.
[3] Xue LOU,Li LIAO,Xing-jun LI,Nan WANG,Shuang LIU,Ruo-mei CUI,Jian XU. Methylation status and expression of TWEAK gene promoter region in peripheral blood of patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1020-1025.
[4] Hua ZHONG,Li-ling XU,Ming-xin BAI,Yin SU. Effect of chemokines CXCL9 and CXCL10 on bone erosion in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1026-1031.
[5] Liang LUO,Wen-gang HUO,Qin ZHANG,Chun LI. Clinical characteristics and risk factors of rheumatoid arthritis with ulcerative keratitis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1032-1036.
[6] Xue-rong DENG,Xiao-ying SUN,Zhuo-li ZHANG. Agreement between ultrasound-detected inflammation and clinical signs in ankles and feet joints in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1037-1042.
[7] Guang-yan MENG,Yun-xiao ZHANG,Yu-xin ZHANG,Yan-ying LIU. Clinical characteristics of central nervous system involvement in IgG4 related diseases [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1043-1048.
[8] Lu ZHANG,Xiao-hong HU,Cheng CHEN,Yue-ming CAI,Qing-wen WANG,Jin-xia ZHAO. Analysis of cervical instability and clinical characteristics in treatment-naive rheumatoid arthritis patients [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1049-1054.
[9] Zhi-bo SONG,Yan GENG,Xue-rong DENG,Xiao-hui ZHANG,Zhuo-li ZHANG. Benefit of ultrasound in the phenotype recognition of psoriatic arthritis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1061-1066.
[10] Hui WEI, Luo-zeng, Ci-dan-yang-zong, Bai-ma-yang-jin. Analysis of clinical characteristics of Henoch-Schonlein purpura patients from different altitudes in plateau areas [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1072-1077.
[11] Jia-yi TIAN,Xia ZHANG,Gong CHENG,Qing-hong LIU,Shi-yang WANG,Jing HE. Serum interleukin-2 receptor α as a clinical biomarker in patients with systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1083-1087.
[12] Ying-jue DU,Wei-chao LIU,Xi CHEN,Yong-jing CHENG. A case report of colchicine-induced myopathy in a patient with chronic kidney disease [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1188-1190.
[13] Wen-xia YI,Cui-jie WEI,Ye WU,Xin-hua BAO,Hui XIONG,Xing-zhi CHANG. Long-term rituximab treatment of refractory idiopathic inflammatory myopathy: A report of 3 cases [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1191-1195.
[14] Yun-shu XIAO,Feng-yun-zhi ZHU,Lan LUO,Xiao-yan XING,Yu-hui LI,Xue-wu ZHANG,Dan-hua SHEN. Clinical and immunological characteristics of 88 cases of overlap myositis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1088-1093.
[15] . [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 1012-1016.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] Author. English Title Test[J]. Journal of Peking University(Health Sciences), 2010, 42(1): 1 -10 .
[2] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 188 -191 .
[3] . [J]. Journal of Peking University(Health Sciences), 2009, 41(3): 376 -379 .
[4] . [J]. Journal of Peking University(Health Sciences), 2009, 41(4): 459 -462 .
[5] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 319 -322 .
[6] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 333 -336 .
[7] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 337 -340 .
[8] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 225 -328 .
[9] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 346 -350 .
[10] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 361 -364 .